Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The approach involves in-depth molecular simulations of the target protein by itself and in complex with its primary partner proteins, paired with ensemble virtual screening that factors in conformational mobility in both the unbound and complex states. The tentative binding pockets are identified at the protein-protein interaction interface and in distant allosteric areas, aiming to capture the full range of mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P23510

UPID:
TNFL4_HUMAN

ALTERNATIVE NAMES:
Glycoprotein Gp34; OX40 ligand; TAX transcriptionally-activated glycoprotein 1

ALTERNATIVE UPACC:
P23510; Q5JZA5; Q8IV74; Q9HCN9

BACKGROUND:
The protein Tumor necrosis factor ligand superfamily member 4, with aliases such as OX40 ligand and Glycoprotein Gp34, is integral to the immune system's function. It enhances T-cell proliferation and cytokine production by binding to TNFRSF4, facilitating a robust immune defense.

THERAPEUTIC SIGNIFICANCE:
Given TNFSF4's critical role in Systemic lupus erythematosus, a disease marked by autoimmune dysregulation, targeting this protein could lead to innovative therapeutic strategies. Understanding the role of TNFSF4 could open doors to potential therapeutic strategies, particularly in diseases where immune system modulation is beneficial.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.